wow-inequalities/02-data/intermediate/wos_sample/415ee4e9942444096508d86cc2aac242-gonzalez-perez-mari/info.yaml

133 lines
4.2 KiB
YAML
Raw Normal View History

2023-09-28 14:46:10 +00:00
abstract: 'Despite of the rapid development of the vaccines against the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take
several months to have enough doses and the proper infrastructure to
vaccinate a good proportion of the world population. In this interim,
the accessibility to the Bacille Calmette-Guerin (BCG) may mitigate the
pandemic impact in some countries and the BCG vaccine offers significant
advantages and flexibility in the way clinical vaccines are
administered. BCG vaccination is a highly cost-effective intervention
against tuberculosis (TB) and many low-and lower-middle-income countries
would likely have the infrastructure, and health care personnel
sufficiently familiar with the conventional TB vaccine to mount
full-scale efforts to administer novel BCG-based vaccine for COVID-19.
This suggests the potential for BCG to overcome future barriers to
vaccine roll-out in the countries where health systems are fragile and
where the effects of this new coronavirus could be catastrophic. Many
studies have reported cross-protective effects of the BCG vaccine toward
non-tuberculosis related diseases. Mechanistically, this
cross-protective effect of the BCG vaccine can be explained, in part, by
trained immunity, a recently discovered program of innate immune memory,
which is characterized by non-permanent epigenetic reprogramming of
macrophages that leads to increased inflammatory cytokine production and
consequently potent immune responses. In this review, we summarize
recent work highlighting the potential use of BCG for the treatment
respiratory infectious diseases and ongoing SARS-CoV-2 clinical trials.
In situations where no other specific prophylactic tools are available,
the BCG vaccine could be used as a potential adjuvant, to decrease
sickness of SARS-CoV-2 infection and/or to mitigate the effects of
concurrent respiratory infections.'
affiliation: 'Ochando, J (Corresponding Author), Inst Salud Carlos III, Dept Immunol,
Transplant Immunol Unit, Natl Ctr Microbiol, Madrid, Spain.
Ochando, J (Corresponding Author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York,
NY 10029 USA.
Gonzalez-Perez, Maria; Ochando, Jordi, Inst Salud Carlos III, Dept Immunol, Transplant
Immunol Unit, Natl Ctr Microbiol, Madrid, Spain.
Sanchez-Tarjuelo, Rodrigo; Ochando, Jordi, Icahn Sch Med Mt Sinai, Dept Oncol Sci,
New York, NY 10029 USA.
Shor, Boris, Manhattan BioSolut, New York, NY USA.
Nistal-Villan, Estanislao, Univ San Pablo Ctr Estudios Univ CEU, Fac Farm, Microbiol
Sect, Dept Ciencias Farmaceut \& Salud, Madrid, Spain.
Nistal-Villan, Estanislao, Univ San Pablo CEU, Inst Med Mol Aplicada IMMA, Fac Med,
Madrid, Spain.'
article-number: '632478'
author: Gonzalez-Perez, Maria and Sanchez-Tarjuelo, Rodrigo and Shor, Boris and Nistal-Villan,
Estanislao and Ochando, Jordi
author-email: Jordi.ochando@mssm.edu.edu
author_list:
- family: Gonzalez-Perez
given: Maria
- family: Sanchez-Tarjuelo
given: Rodrigo
- family: Shor
given: Boris
- family: Nistal-Villan
given: Estanislao
- family: Ochando
given: Jordi
da: '2023-09-28'
doi: 10.3389/fimmu.2021.632478
files: []
issn: 1664-3224
journal: FRONTIERS IN IMMUNOLOGY
keywords: 'Bacille Calmette-Guerin; SARS-CoV-2; vaccination; trained immunity;
cross-protection'
keywords-plus: 'BACILLUS-CALMETTE-GUERIN; RESPIRATORY SYNCYTIAL VIRUS; TRAINED IMMUNITY;
NONSPECIFIC PROTECTION; GUINEA-BISSAU; RECOMBINANT; INFECTION;
RESPONSES; EFFICACY; MEMORY'
language: English
month: MAR 8
number-of-cited-references: '68'
orcid-numbers: 'Ochando, jordi/0000-0001-7037-1681
Nistal-Villan, Estanislao/0000-0003-2458-8833
Gonzalez Perez, Maria/0000-0003-0838-4734
Sanchez Tarjuelo, Rodrigo/0000-0002-3252-2722'
papis_id: 409cc5f0651b9c4f28972a54ac5577cc
ref: Gonzalezperez2021bcgvaccine
researcherid-numbers: 'Ochando, jordi/ABE-2358-2020
Nistal-Villan, Estanislao/GWM-7994-2022
Nistal-Villan, Estanislao/C-6122-2015
'
tags:
- review
times-cited: '43'
title: 'The BCG Vaccine for COVID-19: First Verdict and Future Directions'
2023-10-01 08:15:07 +00:00
type: article
2023-09-28 14:46:10 +00:00
unique-id: WOS:000630922700001
usage-count-last-180-days: '0'
usage-count-since-2013: '4'
volume: '12'
web-of-science-categories: Immunology
year: '2021'